Small molecule induced reactivation of mutant p53 in cancer cells

Allele-Specific p53 Mutant Reactivation

(2012) Xin Yu et al.   CANCER CELL

The rebel angel: mutant p53 as the driving oncogene in breast cancer

(2012) D. Walerych et al.   CARCINOGENESIS

Halogen-Enriched Fragment Libraries as Leads for Drug Rescue of Mutant p53

(2012) Rainer Wilcken et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

First-order rate-determining aggregation mechanism of p53 and its implications

(2012) G. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition

(2012) R. Wilcken et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Microwave-mediated synthesis and manipulation of a 2-substituted-5-aminooxazole-4-carbonitrile library

(2012) John Spencer et al.   TETRAHEDRON LETTERS

Synthesis of a 1,3,5-benzotriazepine-2,4-dione based library

(2012) Irina Chuckowree et al.   TETRAHEDRON LETTERS

Synthesis and biological evaluation of 1,4-benzodiazepin-2-ones with antitrypanosomal activity

(2011) John Spencer et al.   BIOORGANIC & MEDICINAL CHEMISTRY

CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol

(2011) Xiangrui Liu et al.   INTERNATIONAL JOURNAL OF CANCER

Synthesis of a (piperazin-1-ylmethyl)biaryl library via microwave-mediated Suzuki–Miyaura cross-couplings

(2011) John Spencer et al.   TETRAHEDRON LETTERS

Synthesis and solid state study of pyridine- and pyrimidine-based fragment libraries

(2011) John Spencer et al.   TETRAHEDRON LETTERS

Subchronic oral toxicity and metabolite profiling of the p53 stabilizing agent, CP-31398, in rats and dogs

(2011) William D. Johnson et al.   TOXICOLOGY

XDS

(2010) Wolfgang Kabsch   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Features and development ofCoot

(2010) P. Emsley et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Non-oxime pyrazole based inhibitors of B-Raf kinase

(2010) Bradley J. Newhouse et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells

(2010) Shinji Endo et al.   CANCER SCIENCE

Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding

(2010) Joel L. Kaar et al.   PROTEIN SCIENCE

The Tumor Suppressor p53: From Structures to Drug Discovery

(2010) A. C. Joerger et al.   Cold Spring Harbor Perspectives in Biology

Microwave-Mediated Synthesis of an Arylboronate Library

(2010) John Spencer et al.   ACS Combinatorial Science

PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain

(2009) Jeremy M.R. Lambert et al.   CANCER CELL

Blinded by the Light: The Growing Complexity of p53

(2009) Karen H. Vousden et al.   CELL

Antitumor Activity of the Selective MDM2 Antagonist Nutlin-3 Against Chemoresistant Neuroblastoma With Wild-Type p53

(2009) Tom Van Maerken et al.   JNCI-Journal of the National Cancer Institute

Cytoplasmic functions of the tumour suppressor p53

(2009) Douglas R. Green et al.   NATURE

Transcription-independent p53 apoptosis: an alternative route to death

(2009) Daniel Speidel   TRENDS IN CELL BIOLOGY

Structural Biology of the Tumor Suppressor p53

(2008) Andreas C. Joerger et al.   Annual Review of Biochemistry

Targeted rescue of a destabilized mutant of p53 by an in silico screened drug

(2008) F. M. Boeckler et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA